Brilinta Taiwan Post Approval Safety Study

Summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction

Timeline

Start

2015-04-23

Primary completion

2017-02-09

Completion

2017-02-09

Drugs

Indications